Santarus commences Phase I SAN-300 trial
The study is designed to determine the safety, efficacy, pharmacokinetics, pharmacodynamics of single doses of SAN-300. In the trial, the company is evaluating around 60 patients including healthy
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.